Organization | Cancer Research Malaysia

Cancer Research Malaysia Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2018

NCT03686098

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Cancer Research Malaysia

Active Ingredients

Drugs in Phase 2 Trials (5)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

pembrolizumab (keytruda) (1 trial)

talazoparib (talzenna) (1 trial)

Drugs in Other Trials (1)

soybean (1 trial)

Indications

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 6